Does Cyp3a Inducers Interact with Zongertinib?
Cyp3a Inducers and Zongertinib have a major drug interaction according to U.S. FDA drug labeling data. Strong CYP3A4 inducers decrease zongertinib exposure, which may reduce effectiveness of HERNEXEOS. Avoid concomitant use; if unavoidable, increase HERNEXEOS dose. The mechanism involves cyp3a4-mediated metabolism; zongertinib is a cyp3a substrate. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Zongertinib Class
- Kinase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inducers and Zongertinib occurs because cyp3a4-mediated metabolism; zongertinib is a cyp3a substrate. Clinically, this means strong cyp3a4 inducers decrease zongertinib exposure, which may reduce effectiveness of hernexeos. avoid concomitant use; if unavoidable, increase hernexeos dose. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Zongertinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider